Heat shock protein-based cancer vaccines

Expert Review of Vaccines

Volumn 3, Issue 4, 2004, Pages 403-411

  Oki, Yasuhiro ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carcinoma; Chaperone; Lymphoma; Melanoma

Indexed keywords

CANCER VACCINE; CHAPERONE; GLYCOPROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN PEPTIDE COMPLEX 96; ONCOPHAGE; UNCLASSIFIED DRUG;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; KIDNEY CARCINOMA; LYMPHOMA; MELANOMA; MUSCLE WEAKNESS; MYALGIA; PANCREAS CANCER; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN TINGLING; STOMACH CANCER; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS;

EID: 4043126112     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.4.403     Document Type: Review

References (48)

1. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3, 326-333 (1943).
2. Srivastava PK, Amato RJ. Heat shock proteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents. Vaccine 19(17-19), 2590-2597 (2001).
3. Srivastava PK, Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 6(5), 728-732 (1994).
4. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 178(4), 1391-1396 (1993). A landmark study demonstrating that the low-molecular-weight peptides chaperoned by HSPs are responsible for specific immunogenicity against the tumor.
5. + T-cells in vivo. Proc. Natl Acad. Sci. USA 91(8), 3077-3081 (1994).
6. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8(6), 657-665 (1998). An excellent review of HSPs in cancer therapy.
7. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, HSP90 and HSP70. J. Immunol. 152(11), 5398-5403 (1994).
8. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, HSP90, HSP70 and catreticulin. Immunity 14(3), 303-313 (2001).
9. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nature Immunol. 1(2), 151-155 (2000).
10. Binder RJ, Srivastava PK. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc. Natl Acad. Sci. USA 101(16), 6128-6133 (2004). An excellent summary of gp96 modification through CD91.
11. Berwin B, Hart JP, Pizzo SV, Nicchitta CV. Cutting edge: CD91-independent cross-presentation of grp94(gp96)-associated peptides. J. Immunol. 168(9), 4282-4286 (2002).
12. Vabulas RM, Braedel S, Hilf N et al. The endoplasmic reticulum-resident heat shock protein gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J. Biol. Chem. 277(23), 20847-20853 (2002).
13. Asea A, Kraeft SK, Kurt-Jones EA et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nature Med. 6(4), 435-442 (2000).
14. + T-cell effector function. J. Immunol. 172(10), 6087-6092 (2004).
15. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269(5230), 1585-1588 (1995).
16. Kuppner MC, Gastpar R, Gelwer S et al. The role of heat shock protein (HSP70) in dendritic cell maturation: HSP70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur. J. Immunol. 31(5), 1602-1609 (2001).
17. Multhoff G, Mizzen L, Winchester CC et al. Heat shock protein 70 (HSP70) stimulates proliferation and cytolytic activity of natural killer cells. Exp. Hematol. 27(11), 1627-1636 (1999).
18. Multhoff G. Activation of natural killer cells by heat shock proteins 70. Int. J. Hyperthermia 18(6), 576-585 (2002). Comprehensive review on NK cell activation induced by HSP.
19. Gross C, Hansch D, Gastpar R, Multhoff G. Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. Biol. Chem. 384(2), 267-279 (2003).
20. Menoret A, Chandawarkar RY, Srivastava PK. Natural autoantibodies against heat-shock proteins HSP70 and gp96: implications for immunotherapy using heat-shock proteins. Immunology 101 (3), 364-370 (2000).
21. Srivastava PK, Jaikaria NS. Methods of purification of heat shock protein-peptide complexes for use as vaccines against cancers and infectious diseases. Methods Mol. Biol. 156, 175-186 (2001). Review on the methods of HSPPC purification for vaccination.
22. Gordon NF, Clark BL. The challenges of bringing autologous HSP-based vaccines to commercial reality. Methods 32(1), 63-69 (2004).
23. Kovalchin JT, Murthy AS, Horattas MC, Guyton DP, Chandawarkar RY. Determinants of efficacy of immunotherapy with tumor-derived heat shock protein gp96. Cancer Immun. 1, 7-16 (2001).
24. Srivastava PK, DeLeo AB, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl Acad. Sci. USA 83(10), 3407-3411 (1986).
25. Wang XY, Kazim L, Repasky EA, Subjeck JR. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J. Immunol. 166(1), 490-497 (2001).
26. Palladino MA Jr, Srivastava PK, Oettgen HE DeLeo AB. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. Cancer Res. 47(19), 5074-5079 (1987).
27. Srivastava PK, Das MR. The serologically unique cell surface antigen of Zajdela ascitic hepatoma is also its tumor-associated transplantation antigen. Int. J. Cancer 33(3), 417-422 (1984).
28. Janetzki S, Blachere NE, Srivastava PK. Generation of tumor-specific cytotoxic T-lymphocytes and memory T-cells by immunization with tumor-derived heat shock protein gp96. J. Immunother. 21(4), 269-276 (1998).
29. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278(5335), 117-120 (1997).
30. Wang XY, Manjili MH, Park J et al. Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins. Methods 32(1), 13-20 (2004).
31. Nicchitta CV. Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone grp94/gp96. Curr. Opin. Immunol. 10(1), 103-109 (1998).
32. Huang XF, Ren W, Rollins L et al. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res. 63(21), 7321-7329 (2003).
33. Sato K, Torimoto Y, Tumura Y et al. Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice. Blood 98(6), 1852-1857 (2001).
34. Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol. Immunother. 49(9), 476-484 (2000).
35. Robert J, Menoret A, Basu S, Cohen N, Srivastava PR. Phylogenetic conservation of the molecular and immunological properties of the chaperones gp96 and HSP70. Eur. J. Immunol. 31(1), 186-195 (2001).
36. Yedavelli SP, Guo L, Daou ME et al. Preventive and therapeutic effect of tumor-derived heat shock protein, gp96, in an experimental prostate cancer model. Int. J. Mol. Med. 4(3), 243-248 (1999).
37. Heike M, Hertkorn C, Reitsma D et al. Pilot trial of vaccination with autologous tumor-derived gp96 heat shock protein-peptide complex (HSPPC-96) in patients after surgery for gastric carcinoma. Proc. Am. Soc. Clin. Oncol. Abs. 1825, (2000).
38. Hertkom C, Lehr A, Woelfel T et al. Phase I trial of vaccination with autologous tumor-derived gp96 (oncophage) in patients after surgery for gastric cancer. Proc. Am. Soc. Clin. Oncol. Abs. 117, (2002).
39. Eton O, East M, Ross MI et al. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. Proc. Ann. Meet. Am. Assoc. Cancer. Res. Abs. 3463, (2000).
40. Belli F, Testori A, Rivoltini L et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20(20), 4169-4180 (2002). Key report supporting the rationale of ongoing Phase III study.
41. Amato R, Murray L, Wood L et al. Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumor-derived heat shock protein-peptide complex-96 (HSPP-96). Proc. Am. Soc. Clin. Oncol. Abs 1278, (1999).
42. Amato R, Wood L, Savary C et al. Patients with renal cell carcinoma (RCC) using autologous tumor-derived heat shock protein-peptide complex (HSPPC-96) with or without interleukin-2 (IL-2). Proc. Am. Soc. Clin. Oncol. Abs. 1782, (2000).
43. Assikis VJ, Daliani D, Pagliaro L et al. Phase II study of an autologous tumor-derived heart shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). Proc. Am. Soc. Clin. Oncol. 22, Abs. 1552, (2003).
44. Maki RG, Lewis JJ, Janetzki S et al. Phase I study of HSPPC-96 (Oncophage®) vaccine in patients with completely resected pancreatic adenocarcinoma. Eur. J. Cancer Suppl. 1(5), S19 (2003).
45. Younes A. A Phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphoma. Clin. Lymphoma 4(3), 183-185 (2003).
46. Younes A, Fayad LE, Pro B et al. Safety and efficacy of heat shock protein-peptide 96 complex (HSPPC-96) in low-grade lymphoma. Proc. Am. Soc. Clin. Oncol. 22 Abs. 2294, (2003).
47. Mazzaferro V, Coppa J, Carrabba MG et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. 9(9), 3235-3245 (2003).
48. Li Z, Qiao Y, Laska E et al. Autologous leukocyte-derived heat shock protein 70-peptide complex as a vaccine for chronic myelogenous leukemia in chronic phase: an updated Phase I study. Blood 102(11), Abs 3392, (2003).